Annual report [Section 13 and 15(d), not S-K Item 405]

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.25.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Oct. 04, 2023
Feb. 02, 2023
Jan. 11, 2022
May 30, 2019
Dec. 31, 2024
Jan. 05, 2024
Dec. 31, 2023
Sep. 30, 2019
Dec. 10, 2015
First payment owed     $ 145,000   $ 0        
Recognized loss on contingency         (323,184)        
Accrued interest         $ 87,639        
Compensation for services, description         As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month        
Charles River Laboratories, Inc. [Member]                  
Remaining commitment         $ 28,936        
Payment of amended consideration       $ 3,024,476          
BICX Holding Company LLC [Member]                  
Common stock issued upon convertible debt         2,227,575        
Convertible Promissory Note               $ 4,160,000  
Conversion agreement description         Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. As of September 30, 2024, the Public Offering has not yet been abandoned by the Company        
Issuance price         $ 2.00        
Orange County Research Center [Member]                  
Consideration amount     $ 657,640   $ 503,089        
Pellecome [Member]                  
Attorney's fees         $ 235,886        
Attorney's fees received or awarded $ 222,933 $ 222,933              
Interest rate         10.00%        
Pellecome [Member] | January 5, 2024 [Member]                  
Attorney's fees received or awarded         $ 332,503        
Consultant [Member]                  
Issue of common stock to consultant         3,000        
Renumeration amount         $ 1,417        
Alpine Creek [Member]                  
Royalty due         91   $ 91    
Total consideration amount         1,531,926        
Payables to Alpine Creek                 $ 1,215,000
Paid to Alpine Creek         $ 1,620,000        
Payable commitment description         On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of December 31, 2024 and 2023, there are no payments due        
Payable per treatment sold                 $ 100
Profit holding percentage                 50.00%
Board of directors                  
Annual compensation           $ 200,000